02186 LUYE PHARMA
- 2.720
- +0.020+0.74%
LUYE PHARMA News
Luye Pharma Group Ltd. (HKG:2186) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 17.8x Luye Pharma Group Ltd. (HKG:2186) may be sending very bearish signals at the moment, given that almost half of all companies in Hong Kong have P/E ra
[Broker Focus] Tianfeng Securities maintains Luye Pharmaceutical's (02186) “buy” rating, indicating that the main types of core business have large market space
Jinwu Financial News | According to Tianfeng Securities Research Report, Luye Pharmaceutical (02186) announced 2023 results: overall operating revenue of 6.14 billion yuan in 2023, up 2.7% year on year, product sales revenue of 5.63 billion yuan, up 11.2% year on year, and net profit to mother of 533 million yuan, down 11.9% year on year. The decline in net profit is mainly due to a decrease in the share of authorized revenue. The company's overall performance was in line with expectations. The bank mentioned that subsequent sales volume of core products and progress in the research pipeline are worth looking forward to, and there is plenty of room for reasonable valuation. According to this bank, considering the outstanding advantages of the company's new products, there will be many
Huaan Securities: Maintaining Luye Pharmaceutical's (02186) “Buy” Rating Rapid Growth in Sales Revenue in 2023
Huaan Securities is optimistic about the rapid release of new oncology products such as Luye Pharmaceuticals (02186) and Baituwei after they are launched.
Changes in Hong Kong stocks | Luye Pharmaceutical (02186) fell nearly 5% in the afternoon, annual net profit fell 11.9% year-on-year, and sales revenue of oncology products fell 8%
Luye Pharmaceutical (02186) fell nearly 5% in the afternoon. As of press release, it was down 4.58% to HK$2.71, with a turnover of HK$28.295,800.
Luye Pharmaceutical Announces 2023 Annual Results Profit attributable to shareholders of 533 million yuan, a year-on-year decrease of 11.94%
Luye Pharmaceutical (02186) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 6.143 billion yuan (RMB, same below) during the period, an increase of 2.7% over the previous year; profit attributable to shareholders was 533 million yuan, a decrease of 11.94% year on year; and basic profit per share was 14.29 points.
Is There An Opportunity With Luye Pharma Group Ltd.'s (HKG:2186) 27% Undervaluation?
Key Insights The projected fair value for Luye Pharma Group is HK$3.88 based on 2 Stage Free Cash Flow to Equity Luye Pharma Group is estimated to be 27% undervalued based on current share price of
Luye Pharmaceutical Announces 2023 Annual Results
Product sales have grown steadily, and the financial structure has been significantly optimized, Shanghai, March 27, 2024/PRNewswire/ -- On March 27, Luye Pharmaceutical Group (2186.HK) announced its 2023 annual results and business progress to date. During the reporting period, the Group's revenue was about 6.14 billion yuan, up 2.7% year on year; EBITDA was about 2.08 billion yuan, up 14.6% year on year; profit before tax was about 70 billion yuan, up 4.5% year on year. The Group's balance ratio was approximately 46.9%, down 7.6 percentage points from the previous year. Of operating income, production
LUYE PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Global Transdermal Medical Patch Market Analysis 2024-2029, Featuring Novartis, Viatris, Nitto Denko, Luye Pharma, Hisamitsu Pharmaceutical, Medline Industries, Corium, UCB, Teikoku Pharma and More
DUBLIN, March 25, 2024 /PRNewswire/ -- The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been adde
Luye Pharmaceutical (02186.HK) held a board meeting on March 27 to approve annual results
Glonghui, March 14, 丨 Luye Pharmaceutical (02186.HK) announced that the company will hold a board meeting on March 27, 2024 (Wednesday) to approve (among other things) the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and consider paying a final dividend (if any).
LUYE PHARMA: NOTICE OF BOARD MEETING
GLONGHUI ANNOUNCEMENT SELECTION (HK Stocks) | China Telecom (00728.HK) 2023 Net Profit of RMB 30.446 billion increased 10.3% year-on-year
[Today's Focus] China Telecom (00728.HK)'s 2023 net profit of 30.446 billion yuan increased 10.3% year on year China Telecom (00728.HK) announced that in 2023, the company's total operating income was 507.843 billion yuan, up 6.9% year on year; net profit attributable to shareholders of listed companies was 30.446 billion yuan, up 10.3% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 29.553 billion yuan, up 8.7% year on year. The company attaches great importance to shareholder returns and strives to enhance its ability to generate profits and cash flow. 2
Luye Enrolls First Patient Into Phase III Trial of Anti-Cancer Drug
Luye Pharma Group (HKG:2186) said the first patient has been enrolled in a Phase III clinical trial of the firm's investigational anti-cancer drug, the irinotecan hydrochloride liposome injection (LY0
Luye Pharmaceutical (02186.HK): The innovative preparation LY01610 has completed the enrollment of the first patients in phase III clinical trials
Gelonghui, March 4 | Luye Pharmaceutical (02186.HK) announced that irinotecan hydrochloride liposome injection (LY01610), an innovative anti-tumor preparation independently developed by the Group, has completed the enrollment of the first patients in phase III clinical trials. This trial is a multi-center, randomized, open, parallel-designed phase III clinical study to evaluate the efficacy and safety of LY01610 compared to topotecan in patients with recurrent small cell lung cancer (SCLC). LY01610 is expected to be a better treatment for recurrent SCLC. Up to now, no irinotecan hydrochloride liposomes have been approved for the treatment of SCLC in China
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%
Luye Pharma Group's (HKG:2186) LY03010 injectable for schizophrenia and schizoaffective disorder overcame patent challenges during the new drug application review process by the US Food and Drug Admin
Luye Pharmaceutical (02186.HK) paliperidone palmitate sustained-release suspension injection is expected to be approved for marketing in the US as early as this year
Luye Pharmaceutical Group (2186.HK) updated the latest progress of its new drug marketing review for its paliperidone palmitate sustained-release suspension injection (LY03010) in the US on February 1. Currently, the new drug marketing application (NDA) for this product has been accepted by the US Food and Drug Administration (FDA), and no patent infringement lawsuit has been filed within the time limit stipulated in the US Federal Food, Drug, and Cosmetics Act, which means that the LY03010 project's patent challenge in the FDA approval process has been successful. LY03010 is an innovative preparation independently developed by Luye Pharmaceutical to treat schizophrenia
Luye Pharmaceutical (02186): LY03010 successfully challenged the patent in the US NDA review process
Luye Pharmaceutical (02186) announced that the group controlled the US Food and Drug Administration through 505 (b) (2) channels...
Luye Pharma Group (HKG:2186) Stock Falls 4.7% in Past Week as Three-year Earnings and Shareholder Returns Continue Downward Trend
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been particularly tough on longer term Luye Pharma Group Ltd. (HKG:2186) shareholder
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Tianfeng Securities: Target price of HK$4.97 for the initial “buy” rating for Luye Pharmaceuticals (02186)
The Zhitong Finance App learned that Tianfeng Securities released a research report stating that the first payment for Luye Pharmaceuticals (02186) has a “buy” rating. The estimated revenue for 2023-2025 is 61.24/69.91/8.529 billion yuan, and net profit to mother is 6.22/8.09/1,373 billion yuan. Considering the company's obvious advantages in the field of central nervous system and oncology, risperidone and toluvenlafaxine have been approved for listing. Potential varieties such as rotigotine, goserelin, and rubitidine are expected to usher in rapid release after marketing. We are optimistic about the company's development. The target price is HK$4.97. According to the report, the company has matured to go public
Analysis
Price Target
No Data
